Literature DB >> 21308451

Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.

Nuntra Suwantarat1, David A Bobak.   

Abstract

Clostridium difficile infection (CDI) is a leading cause of nosocomial infections and the most important cause of health care-associated diarrhea worldwide. Standard treatment of CDI consists of modifying underlying antibiotic exposure, aggressive supportive measures, and therapy with specific antibiotics, most commonly metronidazole or vancomycin. This general approach to CDI has remained largely unchanged for decades. In an effort to improve outcomes and reduce recurrences of CDI, interest has been renewed in the development of nonantibiotic and adjunct approaches to therapy. In this review, we highlight some of these recent, resurrected, and novel nonantibiotic treatments.

Entities:  

Year:  2011        PMID: 21308451     DOI: 10.1007/s11908-010-0155-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  74 in total

1.  Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea.

Authors:  Ju Young Chang; Dionysios A Antonopoulos; Apoorv Kalra; Adriano Tonelli; Walid T Khalife; Thomas M Schmidt; Vincent B Young
Journal:  J Infect Dis       Date:  2008-02-01       Impact factor: 5.226

2.  Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Authors:  Thomas J Louie; Jennifer Peppe; C Kevin Watt; David Johnson; Rasheed Mohammed; Gordon Dow; Karl Weiss; Stuart Simon; Joseph F John; Gary Garber; Scott Chasan-Taber; David M Davidson
Journal:  Clin Infect Dis       Date:  2006-07-11       Impact factor: 9.079

3.  Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients.

Authors:  Sonia S Yoon; Lawrence J Brandt
Journal:  J Clin Gastroenterol       Date:  2010-09       Impact factor: 3.062

4.  Probiotics have clinical, microbiologic, and immunologic efficacy in acute infectious diarrhea.

Authors:  Chien-Chang Chen; Man-Shan Kong; Ming-Wei Lai; Hsun-Chin Chao; Kuei-Wen Chang; Shih-Yen Chen; Yhu-Chering Huang; Cheng-Hsun Chiu; Wen-Chen Li; Pen-Yi Lin; Chih-Jung Chen; Tzou-Yien Li
Journal:  Pediatr Infect Dis J       Date:  2010-02       Impact factor: 2.129

Review 5.  Prebiotics and probiotics; modifying and mining the microbiota.

Authors:  Eamonn M M Quigley
Journal:  Pharmacol Res       Date:  2010-01-18       Impact factor: 7.658

Review 6.  Clostridium difficile toxins: more than mere inhibitors of Rho proteins.

Authors:  Harald Genth; Stefanie C Dreger; Johannes Huelsenbeck; Ingo Just
Journal:  Int J Biochem Cell Biol       Date:  2008-01-05       Impact factor: 5.085

Review 7.  Potential use of inhibitors of bacteria spore germination in the prophylactic treatment of anthrax and Clostridium difficile-associated disease.

Authors:  Zadkiel Alvarez; Ernesto Abel-Santos
Journal:  Expert Rev Anti Infect Ther       Date:  2007-10       Impact factor: 5.091

8.  Human alpha-defensins inhibit Clostridium difficile toxin B.

Authors:  Torsten Giesemann; Gregor Guttenberg; Klaus Aktories
Journal:  Gastroenterology       Date:  2008-03-10       Impact factor: 22.682

9.  Inhibition of the glucosyltransferase activity of clostridial Rho/Ras-glucosylating toxins by castanospermine.

Authors:  Thomas Jank; Mathias O P Ziegler; Georg E Schulz; Klaus Aktories
Journal:  FEBS Lett       Date:  2008-05-27       Impact factor: 4.124

10.  New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration.

Authors:  Michelle M Merrigan; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  Int J Antimicrob Agents       Date:  2009-03       Impact factor: 5.283

View more
  4 in total

Review 1.  Immune-based treatment and prevention of Clostridium difficile infection.

Authors:  Song Zhao; Chandrabali Ghose-Paul; Keshan Zhang; Saul Tzipori; Xingmin Sun
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection: What's Old Is New Again?

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

Review 3.  The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.

Authors:  Xingmin Sun; Simon A Hirota
Journal:  Mol Immunol       Date:  2014-09-18       Impact factor: 4.407

4.  Systems Modeling of Interactions between Mucosal Immunity and the Gut Microbiome during Clostridium difficile Infection.

Authors:  Andrew Leber; Monica Viladomiu; Raquel Hontecillas; Vida Abedi; Casandra Philipson; Stefan Hoops; Brad Howard; Josep Bassaganya-Riera
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.